According to World Economic Forum, Globally the COVID-19 Pandemic Would Likely end up Costing Between USD 8.1 and USD 15.8 Trillion

According to Centres for Medicare and Medicaid Services, in 2018, NHE rises 4.6% to USD 3.6 trillion (USD 11,172 per person) which accounts for 17.7% of GDP. National health spending will reach to USD 6.2 trillion by 2028 with an average annual rate of 5.4% for 2019-2028. According to Centres for Medicare and Medicaid Services, from 2019-2028, National health spending is expected to reach USD 6.2 trillion by 2028, at an average annual rate of 5.4%.    

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-antimicrobial-susceptibility-testing-market  

Global antimicrobial susceptibility testing market is expected to reach USD 5,986.62 million by 2030 from USD 3,842.21 million in 2022, growing at a CAGR of 5.7% in the forecast period of 2023 to 2030. The demand has increased in both developed as well as in developing countries. The market is growing due to increase in awareness and high level safety associated with testing. The market will grow in the forecasted period with increasing adoption technological advancements.            

Rising global prevalence of infectious diseases, rising prevalence of multi drug resistant organism across the world will drive the market's growth rate

The growing number of epidemic and pandemic events caused by infectious agents such as Neisseria gonorrhea, Salmonella serotype Typhi, Haemophilus influenza, Streptococcus pneumonia are acting as a driver for the market. According to World Economic Forum, the cost of reducing transmission of new disease from tropical forest would cost approximately between USD 22.2 and USD 30.7 billion each year. With the rise in pandemic and epidemic situations around the globe, large numbers of diseases are also transmitting from person to person, propelling the demand for antimicrobial susceptibility testing and acting as a driver for the market.

Report Scope and Market Segmentation

Segment Analysis:

Global antimicrobial susceptibility testing market is categorized into six notable segments which are based on product type, methods, type, application, end user and distribution channel.

• On the basis of product type, global antimicrobial susceptibility testing market is segmented into instruments, consumables & accessories and software & services. In 2022, instruments segment is expected to dominate the global antimicrobial susceptibility testing market and is expected to reach USD 3,621.55 million by 2030 due to high technology adoption by key players in the market.
• On the basis of methods, global antimicrobial susceptibility testing market is segmented into mass spectrometry method, dilution, e-test, disk diffusion, genotypic methods and others. In 2022, disk diffusion segment is expected to dominate the global antimicrobial susceptibility testing market and is expected to reach USD 2,817.51 million by 2030 due to its accurate, reliable, and efficient results.
• On the basis of type, global antimicrobial susceptibility testing market is segmented into anti bacterial, anti fungal testing and others. In 2022, anti bacterial testing segment is expected to dominate the market with 73.3% market share and is expected to reach USD 4493.27 million by 2030 due to wide number of tests available in the market. Manufacturers are developing large number of instruments for bacterial testing.
• On the basis of application, global antimicrobial susceptibility testing market is segmented into market is segmented into clinical diagnostics, drug discovery & development, epidemiology & others. In 2022, clinical diagnostics segment is expected to dominate the global antimicrobial susceptibility testing market and is expected to reach USD 4,382.43 million by 2030 because these tests are most frequently done to detect the microbes to help the microbiologist to get access to better clinical diagnosis.
• On the basis of end user, global antimicrobial susceptibility testing market is segmented into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract research organizations, research centres & academic institutes and others. In 2022, hospitals segment is 53.8% market share and is expected to reach USD 3,227.12 million by 2030 because these antimicrobial tests are performed in hospitals largely. Latest technologies are available in the hospital to diagnose the disease and thus helping healthcare practitioner to treat the patients effectively.

The hospitals segment will dominate the end user segment of the antimicrobial susceptibility testing market

The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

• On the basis of distribution channel, global antimicrobial susceptibility testing market is segmented into direct sales, retail sales and third party distributor. In 2022, direct sales segment is expected to dominate the global antimicrobial susceptibility testing market and is expected to reach USD 4,415.07 million by 2030 because consumers are aware of this distribution channel and they prefer direct sales for seeking the benefits of discounts, bulk buying and easy availability of products.

The direct sales segment will dominate the distribution channel segment of the antimicrobial susceptibility testing market

The direct sales segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

Major Players         

Data Bridge Market Research recognizes the following companies as the market players in market: BD (U.S.), Zhuhai DL Biotech Co., Ltd, Mast Group Ltd. (China), HiMedia Laboratories (U.K.), Thermo Fisher Scientific Inc. (India), Bio-Rad Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Genefluidics, Inc. (U.S.),  Rosco Diagnostica A/S (Denmark), ERBA Group (U.S.), Liofilchem S.r.l. (Italy), MERLIN Gesellschaft für mikrobiologische Diagnostika mbH (Germany), bioMérieux SA (France), Merck KGaA (Germany), Danaher (U.S.), Accelerate Diagnostics, Inc. (U.S.), NuMedii, Inc. (U.S.), and BacterioScan, Inc. (U.S.).

Market Development

• Biomerieux, a major player in the market, has launched WASP, an automated microbiology specimen processing instrument. It automates high-quality processing protocols regardless of specimen type, swabs, urine, and liquid specimen. It requires less user intervention and gives accurate result.
• Accelerate Diagnostics has launched Sophonix MS-Fast, an automated chemiluminescent immunoassay analyzing system for detecting COVID-19 antibodies. It gives result in 30 minutes, has the capacity of running 8 samples per run and gives efficient result.
• BD launched BD phoenix, an automated identification and susceptibility testing system that provides rapid and accurate detection of emerging antimicrobial resistance. It has advanced features such as state-of-the-art data management analyzer, monitors and communicates the results directly to clinicians and laboratories.

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

As per Data Bridge Market Research analysis:

North America is the dominant region in antimicrobial susceptibility testing market during the forecast period 2023 to 2030

As a result of increasing investments in the creation of cutting-edge testing procedures, North America is anticipated to dominate the market. Due to an increase in epidemic and pandemic occurrences and the presence of modern healthcare infrastructure, the United States is the market leader in North America. 

Asia-Pacific is estimated to be the fastest-growing region in antimicrobial susceptibility testing market the forecast period 2023 to 2030

Asia-Pacific is expected to be the fastest-growing region during the forecast period due to major companies entering the market such as Thermo Fisher Scientific Inc. and Bio-Rad Laboratories Inc. that are investing in developing testing methods that favour results with high accuracy and minimal turnaround time.    

COVID-19 Impact

The ongoing COVID-19 epidemic has had a variety of beneficial and negative effects on the healthcare sector. A important issue of AMR was getting less attention at the start of the COVID-19 epidemic as the world battled it. Initially, prescribers used antibiotics indiscriminately to treat and prevent assumed bacterial co-infections because there was no validated treatment for COVID-19. Antimicrobial susceptibility testing is speeding up because of the pandemic's gradual slowdown and its irrational use of antibiotics. Additionally, the global spread of COVID-19 negatively influenced business operations, revenue, and supply and delivery systems. The antimicrobial susceptibility testing market was adversely affected by the widespread implementation of national lockdowns, shelter-in-place, curfews, travel restrictions, and isolation measures, which delayed distributions and affected supply chains of essential equipment and consumables.

For more detailed information about the antimicrobial susceptibility testing market, visit: https://www.databridgemarketresearch.com/reports/global-antimicrobial-susceptibility-testing-market